ArticleTherapeutic advances in gastroenterology2018
Rifaximin has the potential to prevent complications of cirrhosis.
Article in Therapeutic advances in gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00298038 (A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy), which is not on this map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.The Cochrane database of systematic reviews · 2023Pooled it
- Efficacy and Safety of Rifaximin in the Prevention of Recurrent Episodes of Hepatic Encephalopathy: A Systematic Review and Meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Pooled it
- Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis.Hepatology international · 2020Pooled it
- Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis.Hepatology international · 2021Trial
- Disease Modulating Agents in Cirrhosis.Clinics in liver disease · 2026Review
- Article
- Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis.World journal of hepatology · 2025Article
- Review
- Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy.Journal of clinical medicine · 2023Article
- Comparative Analysis of the Efficacy of Different Regimens of 12 Months Rifaximin-Alfa Therapy in Patients with Liver Cirrhosis and Minimal Hepatic Encephalopathy.Diagnostics (Basel, Switzerland) · 2023Article
- Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota.World journal of gastroenterology · 2023Review
- Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy.World journal of gastroenterology · 2023Review
- Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier.Therapeutics and clinical risk management · 2023Review
- The Relationship between Gastrointestinal Health, Micronutrient Concentrations, and Autoimmunity: A Focus on the Thyroid.Nutrients · 2022Review
- Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion.Gastroenterology report · 2021Review
- Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents.Journal of clinical medicine · 2021Review
- The Use of Rifaximin in Patients With Cirrhosis.Hepatology (Baltimore, Md.) · 2021Review
- Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy.Frontiers in pharmacology · 2021Review
- Gut microbiota mediated molecular events and therapy in liver diseases.World journal of gastroenterology · 2020Review
- Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundCirrhosis-related complications are associated with poor prognosis. With our analyses, we examined the potential benefit of rifaximin in reducing the risk of developing cirrhosis-related complications.
methodsAdults with cirrhosis and hepatic encephalopathy (HE) in remission were randomly assigned to receive rifaximin 550 mg twice daily or placebo for 6 months with concomitant lactulose permitted.
resultsOf patients receiving rifaximin (
conclusionRifaximin may reduce the incidence of cirrhosis-related complications and the recurrence of overt HE.[ClinicalTrials.gov identifier: NCT00298038.].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.